{"id":54599,"date":"2026-05-19T15:46:23","date_gmt":"2026-05-19T10:16:23","guid":{"rendered":"https:\/\/financialtelegraph.in\/index.php\/2026\/05\/19\/invicta-diagnostic-limited-reports-fy26-total-income-of-rs-33-04-cr-with-ebitda-margins-above-30-percent\/"},"modified":"2026-05-19T15:46:23","modified_gmt":"2026-05-19T10:16:23","slug":"invicta-diagnostic-limited-reports-fy26-total-income-of-rs-33-04-cr-with-ebitda-margins-above-30-percent","status":"publish","type":"post","link":"https:\/\/financialtelegraph.in\/index.php\/2026\/05\/19\/invicta-diagnostic-limited-reports-fy26-total-income-of-rs-33-04-cr-with-ebitda-margins-above-30-percent\/","title":{"rendered":"Invicta Diagnostic Limited Reports FY26 Total Income of Rs 33.04 Cr with EBITDA Margins Above 30 Percent"},"content":{"rendered":"
\n

\"Invicta<\/p>\n

Mumbai (Maharashtra) [India], May 19:<\/strong> Invicta Diagnostic Limited (NSE \u2013 INVICTA), \u2013<\/strong>one of the leading diagnostic service providers in Maharashtra\u2019s healthcare services sector, has announced its\u00a0Audited Financial Results for H2 FY26<\/p>\n

Key Consolidated Financial Highlights<\/strong><\/p>\n

H2 FY26<\/strong><\/p>\n

\u00b7Total Income of\u00a0\u20b9\u00a015.96 Cr<\/p>\n

\u00b7EBITDA of\u00a0\u20b9\u00a03.55 Cr<\/p>\n

\u00b7EBITDA Margin of 22.24%<\/p>\n

\u00b7Net Profit of\u00a0\u20b9\u00a00.79 Cr<\/p>\n

\u00b7Net Profit Margin of 4.94%\u00a0<\/p>\n

\u00b7EPS of\u00a0\u20b9\u00a00.79<\/p>\n

FY26<\/strong><\/p>\n

\u00b7Total Income increased to\u00a0\u20b9\u00a033.04 Cr from\u00a0\u20b9\u00a030.18 Cr annually<\/p>\n

\u00b7EBITDA increased to\u00a0\u20b9\u00a010.45 Cr from\u00a0\u20b9\u00a09.29 Cr annually<\/p>\n

\u00b7EBITDA Margins increased to 31.63% from 30.78%<\/p>\n

\u00b7Net Profit of\u00a0\u20b9\u00a04.87 Cr<\/p>\n

\u00b7Net Profit Margin of 14.74%<\/p>\n

\u00b7EPS of\u00a0\u20b9\u00a04.90<\/p>\n

During FY26, the Company continued to invest towards its long-term growth strategy and network expansion, resulting in cash outflow of\u00a0\u20b912.96 Cr towards purchase of fixed assets. Depreciation expense increased by approximately 31% to\u00a0\u20b93.25 Cr in FY26 from\u00a0\u20b92.49 Cr in FY25, primarily reflecting higher asset base during the year. As newly added centres continue to mature and scale up operations, the Company expects stronger revenue contribution and improved operating leverage in the coming periods.<\/p>\n

H2 FY26 Key Operational Highlights<\/strong><\/p>\n

\n\n\n\n\n\n
Strategic Entry into Pune Through Joint Venture<\/strong><\/td>\n\u00b7Entered Pune market through a strategic JV with four prominent radiologists\u00b7Company holds 52% stake ensuring management, control and operational oversight\u00a0\u00b7Evaluating opportunities to establish additional diagnostic centres in Pune over next 1 to 2 years, subject to market opportunities and Board approvals\u00b7First centre secured at Market Yard, Pune with 2,425 sq. ft. leased property\u00b7Upcoming centre to offer MRI, CT scan, Mammography, Digital X-Ray and integrated Pathology services<\/td>\n<\/tr>\n
Dadar Centre Commences Commercial Operations<\/strong><\/td>\n\u00b7Commenced commercial operations at Dadar Centre from 30th<\/sup>\u00a0January 2026\u00b7Expanded advanced diagnostics portfolio with PET-CT, CT scan, Sonography, Pathology and X-Ray services\u00b7Strategically located near Tata Memorial Hospital within a high-demand oncology diagnostics cluster\u00b7Centre established with project investment of approximately\u00a0\u20b95.50 Cr<\/td>\n<\/tr>\n
Strategic Acquisition Marks Entry into Nashik<\/strong><\/td>\n\u00b7Received Board and Shareholders\u2019 approval to acquire up to 95% stake in Vinchurkar Diagnostics Private Limited.\u00b7Successfully completed the first phase of strategic acquisition on 8 May 2026, by securing a 51% controlling stake in Vinchurkar Diagnostics Private Limited.\u00a0\u00b7Marks strategic entry beyond Mumbai Metropolitan Region into Nashik healthcare market\u00b7Acquisition to be completed in phased manner with total consideration of\u00a0\u20b97.60 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n
\n\n\n\n
Commenting on the Performance, Mr.\u00a0<\/strong>Sanket Vinod Jain<\/strong>,\u00a0<\/strong>Chairman and Non-Executive Director of\u00a0<\/strong>Invicta Diagnostic\u00a0<\/strong>Limited<\/strong>, said,\u00a0<\/strong>\u201cFY26 has been a landmark year for Invicta Diagnostic Limited as we successfully completed our NSE Emerge listing in December 2025 and concluded the year with a stable financial and operational performance. During FY26, we reported Total Income of\u00a0\u20b933.04 Cr and maintained EBITDA margins in excess of 30%, reflecting strong operating efficiency and disciplined execution.
During the second half of the year, we expanded our presence through our strategic entry into Pune with plans for advanced diagnostic centres, commenced operations at our Dadar Centre with PET-CT and CT Scan facilities near Tata Memorial Hospital, and received Board and Shareholders\u2019 approval to acquire up to 95% stake in Vinchurkar Diagnostics Private Limited in Nashik, strengthening our platform for long term growth across Maharashtra. These investments are expected to support higher scale, improved operational reach, and stronger growth momentum in the coming years.
As we enter FY27, we remain focused on expanding our diagnostics network, strengthening our service portfolio, and driving sustainable growth while maintaining operational efficiency. We remain optimistic about the opportunities ahead and are confident of building on this momentum in the coming years.\u201d<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

About Invicta Diagnostic Limited<\/strong><\/p>\n

Invicta Diagnostic Limited\u00a0<\/a>is a diagnostic services company operating in the Mumbai Metropolitan Region, providing radiology and pathology solutions under its consumer facing brand,\u00a0PC Diagnostics<\/strong>.<\/p>\n

Through the PC Diagnostics brand, the Company offers a comprehensive range of diagnostic services, including radiology and imaging, pathology and clinical laboratory testing, and teleradiology. Its operations are supported by a structured hub and spoke model designed to ensure efficiency, reach, and patient convenience.<\/p>\n

The Company\u2019s\u00a0network comprises 8 diagnostic centers and one centralized laboratory across the MMR region in Maharashtra<\/strong>. This includes one flagship hub in Thane with full testing capabilities, three additional hub centres offering advanced and basic diagnostics, and three spoke centres focused on basic diagnostics and sample collection, supported by a centralized laboratory.<\/p>\n

Invicta Diagnostic Limited places strong emphasis on patient convenience through services such as home sample collection, house calls, and multiple report delivery options. The Company continues to strengthen its presence in MMR while expanding across Maharashtra\u2019s diagnostic market, guided by its focus on quality, affordability, and consistent patient care.<\/p>\n

The company was listed on NSE Emerge on 8th<\/sup>\u00a0December 2025.<\/p>\n

In FY26, the Company recorded a consolidated revenue of\u00a0\u20b933.04\u00a0Cr, an EBITDA of\u00a0\u20b910.45\u00a0Cr, and a net profit of\u00a0\u20b94.87\u00a0Cr.<\/p>\n

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mumbai (Maharashtra) [India], May 19: Invicta Diagnostic Limited (NSE \u2013 INVICTA), \u2013one of the leading diagnostic service providers in Maharashtra\u2019s healthcare services sector, has announced its\u00a0Audited Financial Results for H2 … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":54600,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[448],"class_list":["post-54599","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business","entry"],"_links":{"self":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/54599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/comments?post=54599"}],"version-history":[{"count":0,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/54599\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media\/54600"}],"wp:attachment":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media?parent=54599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/categories?post=54599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/tags?post=54599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}